866-997-4948(US-Canada Toll Free)

Antibody Drugs: Technologies and Global Markets

Published By :

BCC Research

Published Date : Sep 2017

Category :

Biotechnology

No. of Pages : 115 Pages


The global phase change materials (PCM) market reached $681 million in 2015. This market is expected to increase from $810 million in 2016 to $2.0 billion in 2021 at a compound annual growth rate (CAGR) of 20.1% for 2016-2021.
Building and construction market is expected to grow from $210 million in 2016 to $560 million in 2021 at a CAGR of 21.7% from 2016 through 2021.
Commercial refrigeration market is expected to grow from $158 million in 2016 to $392 million in 2021 at a CAGR of 19.9% from 2016 through 2021.
Table of Contents Table of Contents Table of Contents Table of Contents Table of Contents Table of Contents
Chapter 1: Introduction ......................................................................................... 1
Study Goals and Objectives........................................................................................................................... 1
Reasons for Doing This Study ........................................................................................................................ 1
Scope of Report ............................................................................................................................................. 1
Information Sources ...................................................................................................................................... 2
Methodology ................................................................................................................................................. 2
Geographic Breakdown ................................................................................................................................. 3
Analyst's Credentials ..................................................................................................................................... 6
Related BCC Research Reports...................................................................................................................... 6
Chapter 2: Summary and Highlights ....................................................................... 8
Chapter 3: Market and Technology Background ................................................. 11
Antibodies and Antigens ............................................................................................................................. 11
Antibody Functions ..................................................................................................................................... 11
Monoclonal Antibodies ............................................................................................................................... 11
History of Monoclonal Antibodies........................................................................................................... 12
Advantages and Disadvantages of Monoclonal Antibodies .................................................................... 13
Types of Monoclonal Antibodies ............................................................................................................. 13
Manufacturing Technologies of Monoclonal Antibodies ........................................................................ 16
Applications of Monoclonal Antibodies .................................................................................................. 20
Chapter 4: Market Breakdown by Technology Type ............................................ 24
Market by Type ........................................................................................................................................... 24
Market Overview ..................................................................................................................................... 25
Market Revenue ...................................................................................................................................... 26
Market Share ........................................................................................................................................... 27
Market by Region ........................................................................................................................................ 28
Market Overview ..................................................................................................................................... 28
Market Revenue ...................................................................................................................................... 29
Market Share ........................................................................................................................................... 30
Murine Monoclonal Antibodies .............................................................................................................. 31
Chimeric Monoclonal Antibodies ............................................................................................................ 33
Human Monoclonal Antibodies............................................................................................................... 35
Humanized Monoclonal Antibodies ........................................................................................................ 36
Market by Manufacturing Process .............................................................................................................. 38
Market Overview ..................................................................................................................................... 39
Market Revenue ...................................................................................................................................... 39
Market Share ........................................................................................................................................... 40
Market of Murine Monoclonal Antibodies by Manufacturing Process................................................... 41
Market Analysis of Chimeric Monoclonal Antibodies by Manufacturing Process .................................. 43
Market Analysis of Human Monoclonal Antibodies by Manufacturing Process ..................................... 44
Market Analysis of Humanized Monoclonal Antibodies by Manufacturing Process .............................. 46
Chapter 5: Market Breakdown by Application ..................................................... 49
Market by Diseases ..................................................................................................................................... 49
Market Overview ..................................................................................................................................... 49
Market Revenue ...................................................................................................................................... 49
Market Share ........................................................................................................................................... 51
Autoimmune Disease .............................................................................................................................. 52
Solid Tumors ............................................................................................................................................ 58
Lymphoma and Leukemia ....................................................................................................................... 62
Others ...................................................................................................................................................... 67
Chapter 6: Industry Structure .............................................................................. 73
Murine Monoclonal Antibodies .................................................................................................................. 73
Market Leaders ....................................................................................................................................... 73
Market Share ........................................................................................................................................... 73
Chimeric Monoclonal Antibodies ................................................................................................................ 73
Market Leaders ....................................................................................................................................... 73
Market Share ........................................................................................................................................... 74
Humanized Monoclonal Antibodies ............................................................................................................ 75
Market Leaders ....................................................................................................................................... 75
Market Share ........................................................................................................................................... 76
Human Monoclonal Antibodies .................................................................................................................. 77
Market Leaders ....................................................................................................................................... 77
Market Share ........................................................................................................................................... 78
Chapter 7: Regulatory Aspects ............................................................................. 81
New Approvals of Monoclonal Antibodies ................................................................................................. 81
Recalls ......................................................................................................................................................... 83
Safety Alerts ................................................................................................................................................ 83
Chapter 8: Patent Review/ New Developments ................................................... 86
Patent Review ............................................................................................................................................. 86
Patents by Year ........................................................................................................................................ 86
Patents by Type ....................................................................................................................................... 87
Patents by Company................................................................................................................................ 88
Patents by Country .................................................................................................................................. 90
Patents by Assignee ................................................................................................................................. 92
New Developments ..................................................................................................................................... 93
Phase I clinical trials ................................................................................................................................ 93
Phase II clinical trials ............................................................................................................................... 95
Phase III Clinical Trials ............................................................................................................................. 97
Phase IV Clinical Trials ............................................................................................................................. 99
Mergers and Acquisitions ......................................................................................................................... 100
Chapter 9: Analysis of Market Opportunities ..................................................... 103
Technical Issues ......................................................................................................................................... 103
Human anti-mouse antibody (HAMA) Problem ........................................................................................ 103
Factors Affecting mAb Drugs .................................................................................................................... 103
Increasing Prevalence of Chronic Diseases ........................................................................................... 104
Aging Population ................................................................................................................................... 104
Price Regulation..................................................................................................................................... 104
Regulatory Approvals ............................................................................................................................ 104
Increasing Competition between Drug Makers .................................................................................... 104
Advances in Manufacturing Technologies ............................................................................................ 105
Biosimilars ............................................................................................................................................. 105
Mergers and Acquisitions ...................................................................................................................... 105
Licensing Agreements ........................................................................................................................... 105
Chapter 10: Company Profiles ........................................................................... 108
Appendix: Abbreviations .................................................................................... 121
About BCC Research ......................................................................................... 123
About BCC Research.................................................................................................................................. 124
BCC Membership ...................................................................................................................................... 124
BCC Custom Research ............................................................................................................................... 124

List of Table

List of Tables
Summary Table Global Market for Antibody Drugs, by Disease, Through 2022 ($ Millions) ...................... 9
Table 1 Evolution of Monoclonal Antibodies ............................................................................................. 12
Table 2 Advantages and Disadvantages of Monoclonal Antibodies .......................................................... 13
Table 3 Murine Monoclonal Antibodies .................................................................................................... 14
Table 4 Chimeric Monoclonal Antibodies .................................................................................................. 14
Table 5 Humanized Monoclonal Antibodies .............................................................................................. 15
Table 6 Human Monoclonal Antibodies ..................................................................................................... 16
Table 7 Differences between Hybridoma and Recombinant Technologies ............................................... 18
Table 8 Murine Monoclonal Antibodies and Their Applications ............................................................... 20
Table 9 Chimeric Monoclonal Antibodies and Their Applications ............................................................. 21
Table 10 Human Monoclonal Antibodies and Their Applications.............................................................. 21
Table 11 Humanized Monoclonal Antibodies and Their Applications ....................................................... 22
Table 12 Global Sales of Antibody Drugs, by Type, Through 2022 ($ Millions) ......................................... 26
Table 13 Market Shares for Antibody Drugs, by Type, 2016 (%) ............................................................... 27
Table 14 Global Sales of Antibody Drugs, by Region, Through 2022 ($ Millions) ...................................... 30
Table 15 Market Shares for Antibody Drugs, by Region, 2016 (%) ............................................................ 31
Table 16 Global Market for Murine Monoclonal Antibodies, by Region, Through 2022 ($ Millions) ....... 32
Table 17 Global Market for Chimeric Monoclonal Antibodies, by Region, Through 2022 ($ Millions) ..... 34
Table 18 Global Market for Human Monoclonal Antibodies, by Region, Through 2022 ($ Millions)........ 36
Table 19 Global Market for Humanized Monoclonal Antibodies, by Region, Through 2022 ($ Millions) . 38
Table 20 Global Market for Monoclonal Antibodies, by Manufacturing Process, Through 2022 ($ Millions) .................................................................................................................................................. 40
Table 21 Market Shares for Antibody Drugs, by Manufacturing Process, 2016 (%) .................................. 41
Table 22 Global Market for Murine Antibody Drugs, by Manufacturing Process, Through 2022 ($ Millions) .................................................................................................................................................. 42
Table 23 Global Market for Chimeric Monoclonal Antibodies, by Manufacturing Process, Through 2022 ($ Millions) .................................................................................................................................................. 43
Table 24 Global Market for Human Monoclonal Antibodies, by Manufacturing Process, Through 2022 ($ Millions) .................................................................................................................................................. 45
Table 25 Global Market for Humanized Monoclonal Antibodies, by Manufacturing Process, Through 2022 ($ Millions) ......................................................................................................................................... 47
Table 26 Global Sales of Antibody Drugs, by Disease, Through 2022 ($ Millions) ..................................... 50
Table 27 Market Shares for Antibody Drugs, by Disease, 2016 (%) ........................................................... 51
Table 28 Types of Autoimmune Diseases .................................................................................................. 53
Table 29 Global Market for Antibody Drugs in Autoimmune Diseases, by Type, Through 2022 ($ Millions) .................................................................................................................................................. 55
Table 30 Global Market for Antibody Drugs in Autoimmune Diseases, by Region, Through 2022 ($ Millions) .................................................................................................................................................. 57
Table 31 Types of Cancer by the Tissue of Origin ...................................................................................... 58
Table 32 Global Market for Antibody Drugs in Solid Tumors, by Type, Through 2022 ($ Millions) .......... 59
Table 33 Global Market for Antibody Drugs in Solid Tumors, by Region, Through 2022 ($ Millions) ....... 61
Table 34 Types of Leukemia ....................................................................................................................... 63
Table 35 Global Market for Antibody Drugs in Lymphoma and Leukemia, by Type, Through 2022 ($ Millions) .................................................................................................................................................. 64
Table 36 Global Market for Antibody Drugs in Lymphoma and Leukemia, by Region, Through 2022 ($ Millions) .................................................................................................................................................. 66
Table 37 Global Market for Antibody Drugs in Other Diseases, by Type, Through 2022 ($ Millions) ....... 69
Table 38 Global Market for Antibody Drugs in Other Diseases, by Region, Through 2022 ($ Millions) .... 70
Table 39 Leading Manufacturer of Murine Monoclonal Antibodies, 2016 ............................................... 73
Table 40 Leading Manufacturers/Suppliers of Chimeric Monoclonal Antibodies, 2016 ........................... 74
Table 41 Market Shares of Manufacturers/Suppliers of Chimeric Monoclonal Antibodies, 2016 (%) .... 74
Table 42 Leading Manufacturers/Suppliers of Humanized Monoclonal Antibodies, 2016 ....................... 76
Table 43 Market Shares of Manufacturers/Suppliers of Humanized Monoclonal Antibodies, 2016 (%) . 76
Table 44 Leading Manufacturers/Suppliers of Human Monoclonal Antibodies, 2016.............................. 78
Table 45 Market Shares of Manufacturers/Suppliers of Human Monoclonal Antibodies, 2016 (%) ...... 79
Table 46 New Approvals of Monoclonal Antibodies, 2014-January 2017 ................................................. 81
Table 47 Recalls, 2014-January 2017 ......................................................................................................... 83
Table 48 Safety Alerts, 2014-January 2017 ................................................................................................. 84
Table 49 Number of Patents, by Year, 2014-January 2017 ........................................................................ 87
Table 50 Number of Patents, by Type, 2014-January 2017 ....................................................................... 88
Table 51 Number of Patents, by Company, 2014-January 2017 ............................................................... 89
Table 52 Number of Patents, by Country, 2014-January 2017 .................................................................. 90
Table 53 Share of Patents by Country, 2014-January 2017 (No./%) .......................................................... 91
Table 54 Number of Patents, by Assignee, 2014-January 2017................................................................. 92
Table 55 Monoclonal Antibodies in Phase I Clinical Trials ......................................................................... 94
Table 56 Monoclonal Antibodies in Phase II Clinical Trials ........................................................................ 96
Table 57 Monoclonal Antibodies in Phase III Clinical Trials ....................................................................... 98
Table 58 Monoclonal Antibodies in Phase IV Clinical Trials ..................................................................... 100
Table 59 Mergers and Acquisitions of Top Pharmaceutical Companies, 2014-January 2017 ................. 101
Table 60 Abbreviations Used in the Antibody Drug Industry ................................................................... 121

List of Chart

List of Figures
Summary Figure Global Market for Antibody Drugs, by Disease, 2014-2022 ($ Millions) .......................... 9
Figure 1 Global Sales of Antibody Drugs, by Type, 2014-2022 ($ Millions) ............................................... 27
Figure 2 Market Shares of Antibody Drugs, by Type, 2016 (%) ................................................................. 28
Figure 3 Global Sales of Antibody Drugs, by Region, 2014-2022 ($ Millions) ............................................ 30
Figure 4 Market Shares for Antibody Drugs, by Region, 2016 (%) ............................................................. 31
Figure 5 Global Market for Murine Monoclonal Antibodies, by Region, 2014-2022 ($ Millions) ............. 33
Figure 6 Global Market for Chimeric Monoclonal Antibodies, by Region, 2014-2022 ($ Millions) ........... 34
Figure 7 Global Market for Human Monoclonal Antibodies, by Region, 2014-2022 ($ Millions) ............. 36
Figure 8 Global Market for Humanized Monoclonal Antibodies, by Region, 2014-2022 ($ Millions) ....... 38
Figure 9 Global Market for Monoclonal Antibodies, by Manufacturing Process, 2014-2022 ($ Millions) 40
Figure 10 Market Shares for Antibody Drugs, by Manufacturing Process, 2016 (%)................................. 41
Figure 11 Global Market for Murine Antibody Drugs, by Manufacturing Process, 2014-2022 ($ Millions) .................................................................................................................................................. 42
Figure 12 Global Market for Chimeric Monoclonal Antibodies, by Manufacturing Process, 2014-2022 ($ Millions) .................................................................................................................................................. 44
Figure 13 Global Market for Human Monoclonal Antibodies, by Manufacturing Process, 2014-2022 ($ Millions) .................................................................................................................................................. 45
Figure 14 Global Market for Humanized Monoclonal Antibodies, by Manufacturing Process, 2014-2022 ($ Millions) .................................................................................................................................................. 47
Figure 15 Global Sales of Antibody Drugs, by Disease, 2014-2022 ($ Millions)......................................... 51
Figure 16 Market Shares for Antibody Drugs, by Disease, 2016 (%) ......................................................... 52
Figure 17 Global Market for Antibody Drugs in Autoimmune Diseases, by Type, 2014-2022 ($ Millions) .................................................................................................................................................................... 56
Figure 18 Global Market for Antibody Drugs in Autoimmune Diseases, by Region, 2014-2022 ($ Millions) .................................................................................................................................................................... 57
Figure 19 Global Market for Antibody Drugs in Solid Tumors, by Type, 2014-2022 ($ Millions) .............. 60
Figure 20 Global Market for Antibody Drugs in Solid Tumors, by Region, 2014-2022 ($ Millions) ........... 62
Figure 21 Global Market for Antibody Drugs in Lymphoma and Leukemia, by Type, 2014-2022 ($ Millions) .................................................................................................................................................. 65
Figure 22 Global Market for Antibody Drugs in Lymphoma and Leukemia, by Region, 2014-2022 ($ Millions) .................................................................................................................................................. 66
Figure 23 Global Market for Antibody Drugs in Other Diseases, by Type, 2014-2022 ($ Millions) ........... 69
Figure 24 Global Market for Antibody Drugs in Other Diseases, by Region, Through 2022 ($ Millions) .. 71
Figure 25 Market Shares of Manufacturers/Suppliers of Chimeric Monoclonal Antibodies, 2016 (%) .... 75
Figure 26 Market Shares of Manufacturers/Suppliers of Humanized Monoclonal Antibodies, 2016 (%) ............................................................................................................................................................... 77
Figure 27 Market Share of Manufacturers/Suppliers of Human Monoclonal Antibodies, 2016 (%)......... 79
Figure 28 Number of Patents, by Year, 2014-January 2017 ...................................................................... 87
Figure 29 Number of Patents, by Type, 2014-January 2017 ...................................................................... 88
Figure 30 Share of Patents, by Country, 2014-January 2017 (%)............................................................... 92
Figure 31 Number of Patents, by Assignee, 2014-January 2017 ............................................................... 93

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *